Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on June 3, 2016, regarding events occurring on June 2, 2016. The filing details the results of the Company's 2016 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
A quorum of 22,228,379 shares (81.4% of outstanding shares) was present at the meeting. The following actions were taken:
- Director Elections: Three Class I directors were reelected to serve until the 2019 annual meeting:
- Harald Stock, Ph.D.: 17,239,408 votes For.
- John Howe III, M.D.: 16,441,369 votes For.
- Marc Kozin: 17,529,466 votes For.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2016, with 22,040,872 votes For.
- Executive Compensation (Say-on-Pay): Stockholders approved, on an advisory basis, the compensation of named executive officers with 15,373,840 votes For.
- Compensation Vote Frequency: Stockholders approved holding an advisory vote on executive compensation every year, with 15,529,476 votes For the 1-year option.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on business outlook, or specific risk factors. The Board of Directors determined to hold annual advisory votes on executive compensation until the next required frequency vote, expected at the 2022 annual meeting.
Important Facts for Investors to Verify
- Confirm the registrant name is OvaScience, Inc., as the input metadata referenced Tempest Therapeutics, Inc.
- Verify the continued service of Class II and Class III directors whose terms expire in 2017 and 2018, respectively.
- Note the significant number of broker non-votes (4,595,933) on director elections and executive compensation matters.
- Review the proxy statement filed on April 18, 2016, for detailed compensation disclosures referenced in the advisory vote.